Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2021 | Osimertinib + ipilimumab in EGFR-mutated NSCLC

Sonam Puri, MD, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, discusses an going Phase Ib trial which explores the combination of osimertinib, an EGFR tyrosine kinase inhibitor (TKI) with ipilimumab, a monoclonal antibody drug in patients with EGFR mutant non-small cell lung cancer as first line treatment. Data from a past study which looked older generation TKIs combined with ipilimumab showed tremendous improvement for patients in progression-free survival (PFS) and overall survival, but this study was halted due to GI toxicities in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.